Kevin Tang, 10% Owner at Fulcrum Therapeutics, Inc. (FULC), bought 249,946 shares at $3.54 ($891K) on 2026-07-13, disclosed to the SEC on 2026-07-15.
10% holder Kevin Tang executed the largest insider purchase in the company's history by buying 12,966 shares for $45,899.64 on July 13, 2026, signaling confidence despite a 54% year-to-date decline. This move comes as the stock has crashed over 54% in the last year following the FDA's rejection of the lead sickle cell drug pociredir.
The stock is currently trading at $3.59, down 54.96% over the last 90 days and 54.21% over the past year, sitting 77.19% below its 52-week high of $15.74.
The stock faces significant risk with a short interest of 9.76% of the float and the discontinuation of its only clinical program due to FDA cancer-risk concerns, which drove a 51% stock drop in early June.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $3.54 | 12,966 | $46K | 5.2% |
| 2 | $3.56 | 53,651 | $191K | 21.4% |
| 3 | $3.58 | 75,952 | $272K | 30.5% |
| 4 | $3.56 | 107,377 | $382K | 42.9% |
| Total | $3.57 avg | 249,946 | $891K | 100% |
| Filing → |
| FULC | BUY | 2026-07-20 | $595K | — | Filing → |
| BOLD | BUY | 2026-07-16 | $156K | — | Filing → |
| BOLD | BUY | 2026-07-13 | $222K | — | Filing → |